Vera Therapeutics' 2025 net loss wider than expectations

Vera Therapeutics

26/02/2026 12:40

Overview

Biotechnology firm's 2025 net loss of $299.6 mln missed analyst expectations

Loss per share for 2025 missed analyst estimates

Company preparing for potential atacicept launch in mid-2026, pending FDA approval

Outlook

Company expects FDA approval of atacicept by July 7, 2026

Vera Therapeutics plans commercial launch of atacicept in mid-2026

Company expects initial results from Phase 2 trial in 1H 2026

Result Drivers

POSITIVE TRIAL RESULTS - Phase 3 trial of atacicept showed significant reduction in proteinuria, supporting potential FDA approval

FDA PRIORITY REVIEW - FDA granted priority review to atacicept BLA with PDUFA date set for July 7, 2026

STRONG FINANCIAL POSITION - Equity and debt financings raised $800 mln, funding operations beyond atacicept's potential approval and launch

Company press release: ID:nGNXbrDFgs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
Miss
-$4.66
-$4.55 (13 Analysts)
FY Net Income
Miss
-$299.62 mln
-$292.51 mln (10 Analysts)
FY Operating Income
Miss
-$315.47 mln
-$305.86 mln (10 Analysts)
FY Operating Expenses
$315.47 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vera Therapeutics Inc is $73.00, about 75.1% above its February 25 closing price of $41.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)